Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rivoceranib for recurrent or metastatic adenoid cystic carcinoma has been terminated. The update does not include new efficacy or safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma

Drugs mentioned

• Rivoceranib (rivoceranib)

Snippet

Sponsor: Elevar Therapeutics | Conditions: Adenoid Cystic Carcinoma | Phase 2 | Status: TERMINATED